116 related articles for article (PubMed ID: 38626834)
1. Metabolic activation and cytochrome P450 inhibition of piperlonguminine mediated by CYP3A4.
Chi Y; Zhu X; Chen Y; Li X; Jiang Z; Jian X; Lian M; Wu X; Wang L; Sun M; Shi X
Int J Biol Macromol; 2024 May; 268(Pt 2):131502. PubMed ID: 38626834
[TBL] [Abstract][Full Text] [Related]
2. Comparative metabolism of aschantin in human and animal hepatocytes.
Lee MS; Shim HJ; Cho YY; Lee JY; Kang HC; Song IS; Lee HS
Arch Pharm Res; 2024 Feb; 47(2):111-126. PubMed ID: 38182943
[TBL] [Abstract][Full Text] [Related]
3. Hydroxychloroquine is Metabolized by Cytochrome P450 2D6, 3A4, and 2C8, and Inhibits Cytochrome P450 2D6, while its Metabolites also Inhibit Cytochrome P450 3A
Paludetto MN; Kurkela M; Kahma H; Backman JT; Niemi M; Filppula AM
Drug Metab Dispos; 2023 Mar; 51(3):293-305. PubMed ID: 36446607
[TBL] [Abstract][Full Text] [Related]
4. Cytochrome P450 Mediated Bioactivation of Saracatinib.
Chen J; Peng Y; Zheng J
Chem Res Toxicol; 2016 Nov; 29(11):1835-1842. PubMed ID: 27769111
[TBL] [Abstract][Full Text] [Related]
5. Formation in vitro of an inhibitory cytochrome P450 x Fe2+-metabolite complex with roxithromycin and its decladinosyl, O-dealkyl and N-demethyl metabolites in rat liver microsomes.
Yamazaki H; Shimada T
Xenobiotica; 1998 Oct; 28(10):995-1004. PubMed ID: 9849646
[TBL] [Abstract][Full Text] [Related]
6. In Vitro and In Vivo Characterization of Reactive Intermediates of Corynoline.
Mao X; Peng Y; Zheng J
Drug Metab Dispos; 2015 Oct; 43(10):1491-8. PubMed ID: 26261285
[TBL] [Abstract][Full Text] [Related]
7. Cytochrome p450-mediated metabolic activation of diosbulbin B.
Lin D; Li C; Peng Y; Gao H; Zheng J
Drug Metab Dispos; 2014 Oct; 42(10):1727-36. PubMed ID: 25024403
[TBL] [Abstract][Full Text] [Related]
8. Demethylation of neferine in human liver microsomes and formation of quinone methide metabolites mediated by CYP3A4 accentuates its cytotoxicity.
Shen Q; Zuo M; Ma L; Tian Y; Wang L; Jiang H; Zhou Q; Zhou H; Yu L; Zeng S
Chem Biol Interact; 2014 Dec; 224():89-99. PubMed ID: 25451576
[TBL] [Abstract][Full Text] [Related]
9. Inhibitory effects of the main metabolites of Apatinib on CYP450 isozymes in human and rat liver microsomes.
Pang NH; Xu RA; Chen LG; Chen Z; Hu GX; Zhang BW
Toxicol In Vitro; 2024 Mar; 95():105739. PubMed ID: 38042355
[TBL] [Abstract][Full Text] [Related]
10. Metabolic activation of TM5441 in vitro and in vivo: Formation of reactive metabolites and human enzymes involved.
Lang SQ; Lang WH; Yu HY; Wang L
Eur J Pharm Sci; 2020 Feb; 143():105195. PubMed ID: 31852629
[TBL] [Abstract][Full Text] [Related]
11. In vitro and in vivo studies of the metabolic activation of chelidonine.
Liu Y; Peng Y; Zhang Z; Guo X; Ji M; Zheng J
Chem Biol Interact; 2019 Aug; 308():155-163. PubMed ID: 31102647
[TBL] [Abstract][Full Text] [Related]
12. Comparative studies of in vitro inhibition of cytochrome P450 3A4-dependent testosterone 6beta-hydroxylation by roxithromycin and its metabolites, troleandomycin, and erythromycin.
Yamazaki H; Shimada T
Drug Metab Dispos; 1998 Nov; 26(11):1053-7. PubMed ID: 9806945
[TBL] [Abstract][Full Text] [Related]
13. In vitro and in vivo metabolic activation of berbamine to quinone methide intermediate.
Sun Y; Yao T; Li H; Peng Y; Zheng J
J Biochem Mol Toxicol; 2017 Apr; 31(4):. PubMed ID: 27902864
[TBL] [Abstract][Full Text] [Related]
14. Evidence for cytochrome P450 3A4-mediated metabolic activation of SCO-267.
Li C; Li X; Fan A; He N; Wu D; Yu H; Wang K; Jiao W; Zhao X
Biopharm Drug Dispos; 2024 Feb; 45(1):30-42. PubMed ID: 38236698
[TBL] [Abstract][Full Text] [Related]
15. In vitro biotransformation of a novel antimalarial cysteine protease inhibitor in human liver microsomes.
Zhang Y; Guo X; Lin ET; Benet LZ
Pharmacology; 1999 Mar; 58(3):147-59. PubMed ID: 9925971
[TBL] [Abstract][Full Text] [Related]
16. Cytochrome P450 mediated metabolic activation of chrysophanol.
Sun Y; Xin X; Zhang K; Cui T; Peng Y; Zheng J
Chem Biol Interact; 2018 Jun; 289():57-67. PubMed ID: 29698620
[TBL] [Abstract][Full Text] [Related]
17. Screening of 16 major drug glucuronides for time-dependent inhibition of nine drug-metabolizing CYP enzymes - detailed studies on CYP3A inhibitors.
Kahma H; Paludetto MN; Neuvonen M; Kurkela M; Filppula AM; Niemi M; Backman JT
Eur J Pharm Sci; 2024 Jul; 198():106735. PubMed ID: 38423227
[TBL] [Abstract][Full Text] [Related]
18. Metabolism of capsaicin by cytochrome P450 produces novel dehydrogenated metabolites and decreases cytotoxicity to lung and liver cells.
Reilly CA; Ehlhardt WJ; Jackson DA; Kulanthaivel P; Mutlib AE; Espina RJ; Moody DE; Crouch DJ; Yost GS
Chem Res Toxicol; 2003 Mar; 16(3):336-49. PubMed ID: 12641434
[TBL] [Abstract][Full Text] [Related]
19. In vitro assessment of metabolic drug-drug interaction potential of apixaban through cytochrome P450 phenotyping, inhibition, and induction studies.
Wang L; Zhang D; Raghavan N; Yao M; Ma L; Frost CE; Maxwell BD; Chen SY; He K; Goosen TC; Humphreys WG; Grossman SJ
Drug Metab Dispos; 2010 Mar; 38(3):448-58. PubMed ID: 19940026
[TBL] [Abstract][Full Text] [Related]
20. In vitro metabolism of a new cardioprotective agent, KR-32570, in human liver microsomes.
Kim H; Kang S; Kim H; Yoon YJ; Cha EY; Lee HS; Kim JH; Yea SS; Lee SS; Shin JG; Liu KH
Rapid Commun Mass Spectrom; 2006; 20(5):837-43. PubMed ID: 16470676
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
